Company news

Ensysce Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

December 9, 2024

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

December 3, 2024

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

December 2, 2024

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

November 25, 2024

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

November 11, 2024

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 6, 2024

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 7, 2024

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

October 1, 2024

Ensysce Biosciences Receives Notice from Nasdaq

September 26, 2024

Ensysce Biosciences Presenting at Upcoming Meetings

September 23, 2024

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

September 18, 2024

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

September 12, 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

August 28, 2024

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

August 26, 2024

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

August 26, 2024

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

August 13, 2024

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

August 7, 2024

Ensysce Biosciences Provides Mid-Year 2024 Update

July 22, 2024

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

July 8, 2024

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

June 26, 2024

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

June 24, 2024

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

June 5, 2024

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

June 2, 2024

Ensysce Biosciences Regains Compliance with Nasdaq

May 27, 2024

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 19, 2024

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 12, 2024

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

April 24, 2024

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

April 18, 2024

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 8, 2024

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

March 14, 2024

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

February 20, 2024

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

February 14, 2024

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

February 12, 2024

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

February 5, 2024

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

January 30, 2024

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

January 24, 2024

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

January 22, 2024

Ensysce Biosciences Issues 2024 Shareholder Letter

January 7, 2024

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

December 18, 2023

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

December 13, 2023

Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing

November 28, 2023

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

November 27, 2023

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

November 15, 2023

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

November 8, 2023

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

October 23, 2023

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

October 17, 2023

Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium

October 12, 2023

Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023

October 2, 2023

Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

September 25, 2023

Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023

September 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.